Interleukin Genetics Inc. Reports Fourth Quarter and Year End 2012 Financial Results
Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2012.
“In 2012, with the successful completion of the University of Michigan study showing the value of our periodontal disease test, PST®, in guiding preventive dental care, Interleukin Genetics achieved a key milestone on the path to what we believe will be growth in commercialization of our proprietary molecular diagnostic technology,” reported Dr. Ken Kornman, Chief Executive Officer of Interleukin Genetics.
“In 2012, with the successful completion of the University of Michigan study showing the value of our periodontal disease test, PST®, in guiding preventive dental care, Interleukin Genetics achieved a key milestone on the path to what we believe will be growth in commercialization of our proprietary molecular diagnostic technology,” reported Dr. Ken Kornman, Chief Executive Officer of Interleukin Genetics.